South Delhi Pharma, New Delhi, India
Abeyvmy (Bevacizumab Injection)
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email email@example.com to discuss.
Abeyvmy 100 (Bevacizumab) Injection is a prescription medicine. Bevacizumab, sold under the brand name Abeyvmy 100, is a medication used to treat a number of types of cancers and a specific eye disease.
INDICATIONS AND USAGE
Medicine Name: Abeyvmy 100
Generic Name: Bevacizumab
Pack Size: Injection: 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL) in a single-dose vial
Company Name: Mylan.
Abeyvmy 100 is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for Covid19, Colorectal cancer, Lung cancer, Breast cancer, Renal cancers, Brain cancers, Eye disease, Ovarian cancer, Cervical cancer.
South Delhi Pharma can facilitate the supply of “AVASTIN (bevacizumab)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). AVASTIN (bevacizumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What bevacizumab is?
Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for
Studies going on to treat for Covid19 Patients.
Bevacizumab was approved in the United States in February 2004, for use in metastatic colorectal cancer.
In 2006, the U.S. Food and Drug Administration (FDA) approved bevacizumab for use in first-line advanced nonsquamous non-small cell lung cancer in combination with carboplatin/paclitaxel chemotherapy.
In December 2010, the U.S. Food and Drug Administration (FDA) notified its intention to remove the breast cancer indication from bevacizumab.
In 2009, the FDA approved bevacizumab for use in metastatic renal cell cancer (a form of kidney cancer). EU approval was granted in 2007. In the EU, bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adults with advanced and/or metastatic renal cell cancer.
The FDA granted accelerated approval for the treatment of recurrent glioblastoma multiforme in May 2009.
Many diseases of the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy, damage the retina and cause blindness when blood vessels around the retina grow abnormally and leak fluid, causing the layers of the retina to separate. This abnormal growth is caused by VEGF, so bevacizumab has been successfully used to inhibit VEGF and slow this growth.
In 2018, the U.S. Food and Drug Administration (FDA) approved bevacizumab in combination with chemotherapy for stage III or IV of ovarian cancer after initial surgical operation, followed by single-agent bevacizumab.
In the EU, bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in people who cannot receive platinum therapy, is indicated for the treatment of adults with persistent, recurrent, or metastatic carcinoma of the cervix.